← Leaderboards
Ritwik Ghosh
Lynntech, Inc.
$746,930
Attributed
$746,930
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $523.6K · FY2013–15$1M$750K$500K$250K$0
'13
'14
'15
Funding mix
By agency
NIH$746,930 · 3
By mechanism
N43$523,553 · 2
R43$223,377 · 1
Top collaborators
No co-investigators on record.
Most similar at Lynntech, Inc.
Same institution · by research overlap
- Alan J Cisar$5,642,534
- John E Mueller$3,591,378
- Thomas D Rogers$2,693,511
- Season S-S Wong$5,414,920
- Jinseong Kim$1,724,453
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceSignal TransductionValidationInnovationBaseCellsApoptoticDimerizationEpidermal Growth Factor ReceptorBinding (Molecular Function)ApoptosisAntibodiesBreast Cancer CellCancer Cell LineAblationDesignAffinityCommercial ApplicationCell GrowthCancer TherapyClinical EfficacyCo-ImmunoprecipitationsCombined Modality TherapyCancer Patient
Grant awards (4)
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)$299,985
N43 · FY2015 · CA · contact PI
IGF::OT::IGF SIMPLE, INEXPENSIVE UNIT FOR REMOVING CELLS FROM SMALL AMOUNTS OF BLOOD IN RESOURCE-LIMITED SETTINGS$223,568
N43 · FY2015 · AI · contact PI
Novel anti-HER3 Bifunctional Peptide to Augment anti-HER2 Breast Cancer Therapies$69,960
R43 · FY2014 · CA · contact PI
Novel anti-HER3 Bifunctional Peptide to Augment anti-HER2 Breast Cancer Therapies$153,417
R43 · FY2013 · CA · contact PI